Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 340Lymphoma, Non-Hodgkin 295Precursor Cell Lymphoblastic Leukemia-Lymphoma 249Leukemia, Lymphocytic, Chronic, B-Cell 235Lymphoma, Large B-Cell, Diffuse 217Leukemia 186Lymphoma, Follicular 183Lymphoma, Mantle-Cell 167Recurrence 142Hodgkin Disease 141Lymphoma, B-Cell 139Leukemia, Myeloid, Acute 133Burkitt Lymphoma 120Lymphoma, B-Cell, Marginal Zone 94Multiple Myeloma 86Myelodysplastic Syndromes 83Waldenstrom Macroglobulinemia 62Lymphoma, T-Cell, Peripheral 57Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 52Neoplasms 52Lymphoma, T-Cell, Cutaneous 52Hematologic Neoplasms 49Lymphoma, Large-Cell, Anaplastic 43Lymphoma, T-Cell 41Lymphoma, Large-Cell, Immunoblastic 41Leukemia, Myelogenous, Chronic, BCR-ABL Positive 40Mycosis Fungoides 38Leukemia, B-Cell 34Sezary Syndrome 30Myeloproliferative Disorders 29

Interventions

vistusertib 1acalabrutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × DLBCL × Lymphoid × Clear all
NCT03205046 2021-01-06

A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies

Acerta Pharma BV

Phase 1/2 Terminated
25 enrolled 11 charts
Lymphoid

DLBCL

Data powered by HemOnc (CC BY 4.0) Colophon âš¡